Saudi German Hospital's profits leap 1,554% in 2024
Revenues surged by 8.65% year-on-year (YoY) to SAR 2.88 billion as of 31 December 2024 from SAR 2.65 billion, according to the financial results.
Earnings per share (EPS) plunged to SAR 3.06 last year from SAR 0.19 in 2023.
In the first nine months (9M) of 2024, Saudi German Hospital logged net profits valued at SAR 174.86 million, up 21.70% YoY from SAR 143.67 million.
All Rights Reserved - Mubasher Info © 2005 - 2022 Provided by SyndiGate Media Inc. (Syndigate.info).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hi Dubai
an hour ago
- Hi Dubai
Cenomi Retail Signs Share Purchase Agreement to Sell 49.95% Stake to Al-Futtaim
Cenomi Retail, Saudi Arabia's leading retail brand partner, today announced that its founding shareholders have signed a share purchase agreement (SPA) with Al-Futtaim, one of the region's most prominent and diversified private business groups. Pursuant to the SPA, Al-Futtaim will acquire a 49.95% stake in Cenomi Retail from the selling shareholders, namely, Fawaz Abdulaziz Alhokair, Abdul Majeed Abdulaziz Alhokair, Salman Abdulaziz Alhokair, Saudi FAS Holding Company, and FAS Real Estate Company. The shares are priced at SAR 44 each, valuing the transaction at more than SAR 2.5 billion. As part of the completion conditions of the agreement, Al-Futtaim and Cenomi Retail are currently negotiating a shareholder loan agreement pursuant to which Al-Futtaim will extend a shareholder loan of an amount not less than SAR 1.3 billion, upon completion of the transaction, to help strengthen Cenomi Retail's balance sheet and support its next phase of growth, the entry of which is a completion condition for the private transaction between the selling shareholders and Al-Futtaim. This landmark deal represents a major milestone for Cenomi Retail, introducing Al-Futtaim as a long-term strategic shareholder and signaling strong confidence in the company's growth trajectory and market leadership in Saudi Arabia's dynamic retail sector. This strategic investment by Al-Futtaim in Cenomi Retail is a key step in the company's transformation journey. Al-Futtaim brings not only significant capital but also deep retail expertise, operational capabilities, and a strong track record of building successful consumer platforms across the region. The company believes this strategic collaboration will accelerate its ability to seize new opportunities and deliver long-term value to its shareholders. Al-Futtaim is one of the region's most established private business groups, with operations spanning automotive, financial services, real estate, retail, and healthcare across the Middle East, Asia, and Africa. The group brings a proven track record in retail, including exclusive operations of leading Inditex brands like Zara, Massimo Dutti, and Bershka across key markets such as Malaysia, Thailand, and Singapore, as well as other retail operations across the Kingdom of Saudi Arabia, the United Arab Emirates, and Egypt. Their global expertise and operational excellence will further enhance Cenomi Retail's platform and future growth trajectory. Fawaz Abdulaziz Alhokair, in his capacity as one of the selling shareholders of Cenomi Retail in the private transaction, said: 'This transaction marks a transformative milestone for Cenomi Retail and our shareholders. By deleveraging our balance sheet and establishing a stronger financial foundation, we are reinforcing long-term partnerships with stakeholders and positioning the company to deliver sustainable growth and enhanced shareholder value. The entry of Al-Futtaim as a strategic investor in the company will provide it with the investor's deep sector expertise, operational scale, and a shared long-term vision. Al-Futtaim's global retail footprint, financial strength, and presence in the Kingdom make them an ideal strategic investor. This strategic investment unlocks significant value for all stakeholders and aligns with Saudi Arabia's Vision 2030 to diversify the economy and attract foreign investment.' Omar Al Futtaim, Vice Chairman and CEO of Al-Futtaim: 'Our investment in Cenomi Retail reflects our strong confidence in the Kingdom of Saudi Arabia's economy and its long-term Saudi Vision 2030. This investment represents substantial foreign direct investment from the UAE private sector and underscores the robust economic partnership between our countries. It strengthens our presence and customer reach in Saudi Arabia, a strategic market with solid fundamentals and a clear national vision. We see significant opportunities to support Cenomi Retail in enhancing operations, accelerating digital transformation, and expanding its brand portfolio. This partnership also paves the way for further collaborations in the dynamic Saudi market.' Salim Fakhouri, Chief Executive Officer at Cenomi Retail, commented: 'Today's announcement demonstrates that Cenomi Retail is firmly on the right strategic path towards our next phase of growth, focused on scalable, high-performing global brands that drive long-term value to our shareholders. Having Al-Futtaim as a strategic investor enables us to capitalize on their proven capabilities and further solidify our leadership in the retail sector and position us for sustainable growth and compelling shareholder returns.' Upon completion of the transaction, Al-Futtaim will work closely with Cenomi Retail's management and board to drive operational efficiencies, enhance customer offerings, and unlock significant value for all shareholders. The transaction is subject to customary regulatory approvals, including clearance from the General Authority for Competition in Saudi Arabia, and other contractual conditions. Further updates will be provided as the transaction progresses. Cenomi Retail was supported by its exclusive financial advisor, Lazard, throughout this transaction execution. J.P. Morgan was appointed by Al-Futtaim as its exclusive financial advisor with respect to the transaction.
Zawya
2 hours ago
- Zawya
FaatGo Officially Launches: A Hong Kong-Based Legal Platform Specializing in Criminal Defence and Injury Compensation
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - In response to the increasing demand for accessible and trustworthy legal information, FaatGo ( has officially launched as a new digital legal platform focused on two of the most pressing legal needs in Hong Kong: criminal defence and personal injury compensation. Designed to address the information gap faced by many residents when encountering legal trouble, the platform provides professionally written legal content, free consultation tools, and direct access to experienced lawyers—without intermediaries or commission-based referrals. The platform offers in-depth legal insights and resources in two major areas. First, FaatGo covers a wide range of common criminal offences, including indecent assault, physical assault, criminal intimidation, theft, money laundering, and drug-related offences. Each topic is explained clearly and precisely, with a focus on legal procedures, sentencing considerations, and practical steps to be taken after arrest or charge. Second, the platform also features comprehensive guides on work injury and traffic accident compensation, helping victims understand their entitlements, calculation methods, documentation requirements, and potential for pursuing additional damages beyond basic insurance. The content is developed in consultation with legal practitioners and aims to simplify what are often highly complex legal processes. All materials are published in Traditional Chinese and tailored to the Hong Kong legal context. Legal information is structured for clarity and ease of understanding, without the use of excessive legal jargon. The platform is specifically designed to empower users to understand their legal position and take action accordingly, whether they are facing prosecution or seeking rightful compensation. FaatGo also provides a free legal consultation form, allowing individuals to submit a summary of their case. The internal team will assess the information and match the user with a suitable lawyer for an initial legal opinion. The service is free of charge, with no commissions or obligations, and all consultations are handled directly by qualified legal professionals. A verified criminal defence lawyer directory is also available for those who wish to engage legal representation independently. Since its soft launch, FaatGo has already supported multiple individuals, including families seeking mitigation strategies for loved ones facing charges, and injured workers who were initially unaware of their full compensation rights. These early successes reflect the platform's commitment to delivering fair, unbiased, and timely legal assistance to those who need it most. FaatGo operates under the principle that legal knowledge should not be limited to a privileged few, but rather made available and understandable to all. By providing regularly updated articles, case studies, and consultation tools, the platform aims to improve public legal literacy and ensure that legal support is accessible in moments of real need. Hashtag: #FaatGo The issuer is solely responsible for the content of this announcement. HKFindLawyer
Zawya
2 hours ago
- Zawya
IVD Medical Holding Limited (01931.HK): Officially launched the application for the US stablecoin license and accelerated the landing of the IVDNewCo Exchange ecosystem
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 – IVD Medical Holding Limited( - Forward-looking layout of the historical opportunity of the US "Genius Act", the IVDD stablecoin plan is gathering momentum to set sail and build a new global infrastructure for medical innovative drugs RWA! In the wave of deep integration of global digital finance and medical innovation, IVD Medical Holding Limited( took the lead in building the "NewCo+RWA" Web3 exchange ecosystem (IVDNewCo Exchange) with the construction of medical innovative drugs high-tech assets as the core and the supporting stablecoin "IVDDollar" (IVDD) plan as the core strategy, leading the digital revolution of global medical innovation assets. On July 20, 2025, the Board of Directors is pleased to announce that the US subsidiary carrying the Group's aforementioned core strategic mission has landed, and the IVDNewCo Exchange ecosystem has officially landed on the international financial stage. The company released the latest announcement today, officially announcing two milestones: the US wholly-owned subsidiary IVD GROUP INC. has completed registration, and the Group has officially started the process of submitting a stablecoin license application to the US regulator through the subsidiary; at the same time, the Web3 exchange ecosystem with medical innovative drug NewCo assets as the core - IVDNewCo Exchange and its supporting stablecoin IVDD have entered a substantive stage. This strategic move not only marks the Group's leading position in the field of compliant digital finance for medical innovative drugs, but also heralds a revolutionary breakthrough in the global medical asset liquidity and value conversion model. 1. Strategic opportunities under global regulatory resonance On July 18, 2025, local time, US President Trump signed the "Guidance and Establishment of the United States Stablecoin National Innovation Act" (hereinafter referred to as the "Genius Act") at the White House, establishing the legal status of stablecoins as "digital dollars". The implementation of this bill, together with the Stablecoin Ordinance of the Hong Kong Special Administrative Region, which will take effect on August 1, forms a regulatory synergy between the East and the West, and jointly builds the compliance cornerstone of the global stablecoin market. The report of the China Banking Research Institute pointed out that currently 99% of the world's stablecoins are anchored to US dollar assets, and US Treasury bonds have become the core choice of stablecoin reserve assets due to their low risk and high liquidity. In this context, the Group proactively laid out the application for the US stablecoin license, and on July 20 officially announced that the US subsidiary had initiated the process of submitting application materials to regulatory agencies such as the US SEC and CFTC, becoming one of the very few listed companies in the Hong Kong stock market that has completed the "Hong Kong + US" dual hub compliance architecture layout. The strategic layout of the Group is deeply in line with the global regulatory trend. By establishing the US subsidiary IVD GROUP INC., we not only meet the strict requirements of the "Genius Act" for 100% reserve asset coverage and independent auditing of stablecoin issuers, but also rely on the sandbox mechanism of the Hong Kong "Stablecoin Ordinance" to build a cross-regional regulatory endorsement system. This dual hub model provides the IVDNewCo Exchange ecosystem with globally rare compliant liquidity support, enabling the Group to establish a first-mover advantage in the "Hong Kong Stock Stablecoin Concept Sector". 2. Technological Innovation: "NewCo+RWA+Stablecoin" Reconstructs the Value Chain of Medical Innovative Drug Assets The core breakthrough of the IVDNewCo Exchange ecosystem lies in the deep integration of Web3 technology and medical innovative drug assets. Relying on the commercial network covering 1,674 tertiary hospitals in China and the ability to acquire high-quality NewCo assets around the world, the Group has created the world's first RWA (real world asset) tokenization platform focusing on medical innovative drugs. The platform achieves the following innovations through blockchain technology: 1). Asset tokenization: converting innovative drug assets such as ADC drugs, bi-antibody therapy, and cell gene therapy in the clinical stage into tradable and divisible digital certificates to break through the liquidity bottleneck of traditional medical assets; 2). Compliance financial infrastructure: establish an underlying architecture to support the issuance, trading and settlement of IVDD stablecoins, ensuring that each $1 stablecoin corresponds to ultra-short-term U.S. Treasury bonds and other low-risk assets, meeting the U.S. SEC's "1:1 redeemable" requirements; 3). Coin-stock linkage mechanism: coordinate with Nasdaq's dual primary listing plan to explore the compound value creation model of "digital assets + traditional equity" to attract two-way inflows of traditional medical capital and crypto-native funds. The implementation of this technical architecture has been strongly supported by industry data. Public information shows that the current global innovative drug market has exceeded US$1.2 trillion, and China accounts for 6% of the market with a scale of RMB 450 billion, with an annual compound growth rate of 20.3%. Through the RWA platform, the Group expects to significantly improve the financing efficiency of innovative drug assets, while lowering the entry threshold for investors, allowing small and medium-sized investors around the world to participate in the medical innovation field that was originally limited to institutional investment. 3. Ecological synergy: creating a new paradigm for medical finance The Group's strategic advancement has always followed the three-dimensional path of "regulatory compliance-technological innovation-ecological synergy". In the United States, IVD GROUP INC.'s license application strictly follows the requirements of the Genius Act for reserve asset transparency, anti-money laundering (AML) and network security. Its technical system has passed a third-party security audit to ensure that smart contracts are free of loopholes; in Hong Kong, the Group will actively promote participation in the HKMA's stablecoin sandbox program to test reserve asset management and cross-border payment scenarios, laying the foundation for license application. More importantly, the implementation of the IVDNewCo Exchange ecosystem is reshaping the value chain of innovative medical drugs. Under the traditional model, the research and development of innovative drugs requires a cycle of up to 10 years, and 80% of the funds are concentrated in the clinical stage. Through the RWA platform, the Group can monetize clinical-stage assets in advance, provide pharmaceutical companies with low-cost financing channels, and provide investors with dynamic returns linked to the progress of drug development. For example, an ADC drug in Phase II clinical trials can attract global capital participation through tokenization, and its development progress data will be uploaded to the chain in real time to ensure that investors' rights and interests are transparent and traceable. 4. Industry Impact and Future Outlook The Group's strategic initiatives have attracted widespread attention from the capital market and the industry. After the announcement on the 17th, IVD Medical's share price opened sharply higher on the 18th, closing at HK$2.95, up 20.41% throughout the day, with a turnover exceeding HK$9.4886 million and a market value of HK$4.783 billion. Behind the market data is investors' strong confidence in the cross-border integration of "NewCo+RWA+stablecoin". Looking ahead, the Group will continue to deepen the three strategic directions of compliance expansion, technology deepening and ecological integration. Against the backdrop of the global low interest rate environment and the surge in demand for medical innovation, it will use Web3 technology as a bridge to connect traditional medical capital and digital financial innovation. We firmly believe that through compliance layout and technological innovation, the IVDNewCo Exchange ecosystem will become a value amplifier for global innovative medical drug assets, creating a win-win situation for patients, pharmaceutical companies and investors. Hashtag: #IVDMedicalHoldingLimited The issuer is solely responsible for the content of this announcement. IVD Medical Holding Limited
